Galectin Therapeutics (GALT) Held by Superinvestors
GALECTIN THERAPEUTICS INC (GALT) is currently held by 1 superinvestors tracked by InsiderSet, with a combined reported market value of approximately $201,112 based on the latest available SEC Form 13F filings for the quarter ended June 30, 2026.
Renaissance Technologies LLC is currently the largest disclosed institutional shareholder of GALT tracked by InsiderSet, reporting ownership valued at approximately $201,112 in its June 30, 2026 SEC Form 13F filing. Based on current market prices and the latest disclosed share count, the position is now estimated to be worth approximately $170,771.42, representing an estimated loss of -15.09% since the filing period.
The top 10 institutional shareholders tracked on this page collectively account for approximately 100% of the total disclosed GALT value among the investors covered in this analysis. Major shareholders include Renaissance Technologies LLC, and several other long-term asset managers with concentrated positions in GALECTIN THERAPEUTICS INC (GALT).
This page ranks the largest institutional GALT shareholders using publicly disclosed SEC Form 13F data, including reported values, estimated current holding values, portfolio allocation percentages, ownership concentration metrics, and historical holding changes across major hedge funds and investment firms.
| Name | Investor/Manager | Portfolio % | Quantity | Reported Balance | Current Estimated Value | Gain/loss Since Filing | Estimated Portfolio Performance |
|---|---|---|---|---|---|---|---|
| Renaissance Technologies LLC | Jim Simons | 0.00% | 43,343 | $201,112 | $170,771 | -$30,341 | -15.09% |
Frequently asked questions about GALT
Who are the largest superinvestors holding GALT?
The largest superinvestors holding GALT in the latest SEC Form 13F filings include Renaissance Technologies LLC. InsiderSet ranks these superinvestors by their latest reported GALT position.
What does the GALT superinvestors page include?
This page tracks GALT positions reported by a curated group of notable institutional investors and fund managers through SEC Form 13F. GALECTIN THERAPEUTICS INC (GALT) on this page reflects disclosed 13F holdings among those superinvestors, not every institutional shareholder of the stock.
How many superinvestors hold GALT?
InsiderSet currently tracks 1 superinvestors reporting GALT holdings in the latest available 13F data. This is the curated set on this page, not the total number of institutions that own GALT.
How much GALT stock do superinvestors hold?
Superinvestors tracked by InsiderSet disclosed approximately $201,112 in GALT holdings for Q2 2026. This figure is reported 13F value as of the filing period, not necessarily today's market value, and it covers the curated superinvestors on this page rather than every institutional filer.
When were GALT superinvestor holdings last updated?
The latest GALT superinvestor holdings on InsiderSet are based on SEC Form 13F filings for the quarter ended June 30, 2026. Form 13F filings are generally reported after the quarter ends, so the holdings shown represent the latest publicly disclosed positions rather than real-time holdings.
Are superinvestor GALT holdings real-time?
No. Form 13F data is not real-time. It represents positions reported by these superinvestors as of the end of the reporting quarter. A superinvestor may have changed its GALT position after the reporting date.
Are superinvestors buying or selling GALT?
Buying and selling can be analyzed by comparing GALT positions across consecutive 13F reporting periods. InsiderSet's GALT Ownership Changes page shows institutions that increased, reduced, initiated, or exited positions based on reported 13F holdings. View GALT ownership changes.
How have superinvestor GALT holdings changed over time?
InsiderSet tracks GALT holdings among these superinvestors across multiple 13F reporting periods, so holder counts, reported value, and reported shares can be compared over time.